How Cytonics' Developed a Revolutionary Treatment for Osteoarthritis, Solving a $240B Problem

Sponsored Content by Cytonics

Robot holding large capsule
(Image credit: Cytonics)

More than 600 million people worldwide suffer from osteoarthritis (OA), a debilitating joint disease that destroys mobility and quality of life. And for a long time, painkillers and corticosteroids were among the only “treatments” available for this joint-degrading disease.

Then Cytonics came along and developed a way to target the disease at the molecular level. 


Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. Kiplinger may receive monetary compensation by the issuer, or its agency, for publicizing the offering of the issuer’s securities. Kiplinger and the issuer of this offering make no promises, representations, warranties or guarantees that any of the services will result in a profit or will not result in a loss.

To continue reading this article
please register for free

This is different from signing in to your print subscription

Why am I seeing this? Find out more here

This content is part of a paid partnership